ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis.Annals of surgery · 2014Pooled it
- Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situ.Breast cancer (Tokyo, Japan) · 2016Trial
- Clinicopathological characteristics and potential impact of previous treatment history in metachronous contralateral breast cancer: Insights from a real-world retrospective study.Oncology letters · 2026Article
- CBCRisk-Mastectomy: A Prediction Tool to Aid Contralateral Prophylactic Mastectomy Decision-Making.The Journal of surgical research · 2026Article
- CBCRisk-Mastectomy: A Risk Prediction Tool to Aid Contralateral Prophylactic Mastectomy Decision Making.medRxiv : the preprint server for health sciences · 2026Article
- Trends in Dose to the Contralateral Breast from Breast Cancer Radiotherapy in the United States.Radiation research · 2025Article
- Global trends and modifiable risk factors for atopic dermatitis incidence: Insights from GBD 2021.The journal of allergy and clinical immunology. Global · 2025Article
- Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 2016.NPJ breast cancer · 2025Article
- Misclassification of second primary and recurrent breast cancer in the surveillance epidemiology and end results registry.Cancer causes & control : CCC · 2025Article
- Hormone Receptor Positive Breast Cancer in Young Women: A Review.Journal of surgical oncology · 2025Review
- Survival analysis for patients with metachronous contralateral breast cancer: Insights from a retrospective study.Oncology letters · 2024Article
- Determining the Need for Metastatic Staging in Patients with Bilateral Breast Cancers.Current oncology (Toronto, Ont.) · 2024Article
- Society of Surgical Oncology Breast Disease Site Working Group Statement on Contralateral Mastectomy: Indications, Outcomes, and Risks.Annals of surgical oncology · 2024Review
- Contralateral prophylactic mastectomy in a rural population: A single-institution experience.Surgery open science · 2024Article
- Risk factors of developing contralateral breast cancer after first primary breast cancer treatment.Cancer reports (Hoboken, N.J.) · 2024Article
- Trends in Radiation Dose to the Contralateral Breast During Breast Cancer Radiation Therapy.Radiation research · 2023Article
- Explaining risks and benefits of loco-regional treatments to patients.Breast (Edinburgh, Scotland) · 2023Article
- Survival After Contralateral Secondary Breast Cancer by Age Group in California.Annals of surgical oncology · 2023Article
- Survival Outcomes in Women with Unilateral, Triple-Negative, Breast Cancer Correlated with Contralateral Prophylactic Mastectomy.Annals of surgical oncology · 2023Article
- Does a brief surgeon training in negotiation theory principles decrease rates of contralateral prophylactic mastectomy?Breast cancer research and treatment · 2023Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeContralateral breast cancer (CBC) is the most frequent new malignancy among women diagnosed with a first breast cancer. Although temporal trends for first breast cancers have been well studied, trends for CBC are not so well established. PATIENTS AND
methodsWe examined temporal trends in CBC incidence using US Surveillance, Epidemiology, and End Results database (1975 to 2006). Data were stratified by estrogen receptor (ER) status of the first breast cancer for the available time period (1990+). We estimated the annual percent change (EAPC) in CBC rates using Poisson regression models adjusted for the age at and time since first breast cancer diagnosis.
resultsBefore 1985, CBC incidence rates were stable (EAPC, 0.27% per year; 95% CI, -0.4 to 0.9), after which they declined with an EAPC of -3.07% per year (95% CI, -3.5 to -2.7). From 1990 forward, the declines were restricted to CBC after an ER-positive cancer (EAPC, -3.18%; 95% CI, -4.2 to -2.2) with no clear decreases after an ER-negative cancer. Estimated current age-specific CBC rates (per 100/year) after an ER-positive first cancer were: 0.45 for first cancers diagnosed before age 30 years and 0.25 to 0.37 for age 30 years or older. Rates after an ER-negative cancer were higher: 1.26 before age 30 years, 0.85 for age 30 to 35 years, and 0.45 to 0.65 for age 40 or older.
conclusionResults show a favorable decrease of 3% per year for CBC incidence in the United States since 1985. This overall trend was driven by declining CBC rates after an ER-positive cancer, possibly because of the widespread usage of adjuvant hormone therapies, after the results of the Nolvadex Adjuvant Trial Organisation were published in 1983, and/or other adjuvant treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.